Skip to main content
Journal cover image

Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults.

Publication ,  Journal Article
Mulligan, MJ; Russell, ND; Celum, C; Kahn, J; Noonan, E; Montefiori, DC; Ferrari, G; Weinhold, KJ; Smith, JM; Amara, RR; Robinson, HL ...
Published in: AIDS Res Hum Retroviruses
July 2006

A vaccine consisting of DNA priming followed by recombinant modified vaccinia Ankara (rMVA) boosting has achieved long-term control of a pathogenic challenge with a chimera of simian and human immunodeficiency viruses (SHIV-89.6P) in rhesus macaques. Based on these results, clade B HIV-1 DNA and rMVA immunogens have been developed for trials in humans. We conducted a first-time in humans phase I safety trial using the pGA2/JS2 (JS2) HIV-1 DNA priming vector expressing Gag, Pol, Env, Tat, Rev, and Vpu. Thirty HIV-uninfected adults were vaccinated with 0.3 or 3 mg of JS2 DNA, or a saline placebo, by intramuscular injection at months 0 and 2. Both doses of DNA were safe and well-tolerated with no differences between the control, 0.3 mg, or 3 mg groups (n = 6, 12, and 12, respectively) through 12 months of postvaccination follow- up. A chromium-release assay using fresh peripheral blood mononuclear cells (PBMCs) and a validated IFN-gamma ELISpot assay with frozen PBMCs failed to detect CD4(+) or CD8(+) HIV-1-specific T cell responses. HIV-specific neutralizing antibodies were also not detected. The vaccine is being further developed as a priming vector for a combined DNA plus rMVA prime/boost HIV vaccination regimen.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

AIDS Res Hum Retroviruses

DOI

ISSN

0889-2229

Publication Date

July 2006

Volume

22

Issue

7

Start / End Page

678 / 683

Location

United States

Related Subject Headings

  • Virology
  • Vaccinia virus
  • Vaccines, DNA
  • T-Lymphocytes, Cytotoxic
  • Statistics, Nonparametric
  • Plasmids
  • Male
  • Interferon-gamma
  • Humans
  • HIV-1
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mulligan, M. J., Russell, N. D., Celum, C., Kahn, J., Noonan, E., Montefiori, D. C., … NIH/NIAID/DAIDS HIV Vaccine Trials Network, . (2006). Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses, 22(7), 678–683. https://doi.org/10.1089/aid.2006.22.678
Mulligan, M. J., N. D. Russell, C. Celum, J. Kahn, E. Noonan, D. C. Montefiori, G. Ferrari, et al. “Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults.AIDS Res Hum Retroviruses 22, no. 7 (July 2006): 678–83. https://doi.org/10.1089/aid.2006.22.678.
Mulligan MJ, Russell ND, Celum C, Kahn J, Noonan E, Montefiori DC, et al. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses. 2006 Jul;22(7):678–83.
Mulligan, M. J., et al. “Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults.AIDS Res Hum Retroviruses, vol. 22, no. 7, July 2006, pp. 678–83. Pubmed, doi:10.1089/aid.2006.22.678.
Mulligan MJ, Russell ND, Celum C, Kahn J, Noonan E, Montefiori DC, Ferrari G, Weinhold KJ, Smith JM, Amara RR, Robinson HL, NIH/NIAID/DAIDS HIV Vaccine Trials Network. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses. 2006 Jul;22(7):678–683.
Journal cover image

Published In

AIDS Res Hum Retroviruses

DOI

ISSN

0889-2229

Publication Date

July 2006

Volume

22

Issue

7

Start / End Page

678 / 683

Location

United States

Related Subject Headings

  • Virology
  • Vaccinia virus
  • Vaccines, DNA
  • T-Lymphocytes, Cytotoxic
  • Statistics, Nonparametric
  • Plasmids
  • Male
  • Interferon-gamma
  • Humans
  • HIV-1